Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

BSH 2023 and Lymphoma View overview page

1:52
PETReA: evaluating PET-adapted maintenance therapy approaches for patients with follicular lymphoma
Kim Linton • 24 Apr 2023
1:24
The changing landscape of BTK inhibitor therapy in patients with MZL
Kim Linton • 24 Apr 2023
1:16
The importance of multidisciplinary collaboration in the classification of lymphomas
Daphne de Jong • 23 Apr 2023
2:03
Novel treatment approaches for early-stage DLBCL
Wendy Osborne • 24 Apr 2023
1:20
Improving patient outcomes in CTCL: clinical collaboration and novel agents
Wendy Osborne • 24 Apr 2023
2:19
Session highlights: autoSCT in T-cell lymphoma, classification updates and fertility preservation
Wendy Osborne • 24 Apr 2023
4:05
Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL
Roni Shouval • 27 Apr 2023
3:09
MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma
Kim Linton • 24 Apr 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
1:01
Pitfalls in the diagnosis of lymphoid malignancies: interpreting PET scans
Wendy Osborne • 24 Apr 2023
1:18
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
Wendy Osborne • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023
1:51
REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma
Kim Linton • 24 Apr 2023
0:44
Clinical efficacy and safety of CT-P10 in patients with DLBCL
Mark Bishton • 24 Apr 2023
1:44
Updates in the WHO classification for lymphoma and how this may impact clinical practice
Daphne de Jong • 23 Apr 2023
The content of VJHemOnc is intended for healthcare professionals